Cibc World Market Inc. Purchases 7,112 Shares of Amgen Inc. $AMGN

Cibc World Market Inc. lifted its position in Amgen Inc. (NASDAQ:AMGN) by 6.3% in the 4th quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 119,731 shares of the medical research company’s stock after acquiring an additional 7,112 shares during the period. Cibc World Market Inc.’s holdings in Amgen were worth $39,189,000 as of its most recent SEC filing.

Several other institutional investors have also recently made changes to their positions in the company. Greenspring Advisors LLC raised its position in shares of Amgen by 2.0% in the 4th quarter. Greenspring Advisors LLC now owns 6,120 shares of the medical research company’s stock worth $2,003,000 after acquiring an additional 120 shares in the last quarter. Archvest Wealth Advisors Inc. bought a new position in shares of Amgen in the 4th quarter worth approximately $1,190,000. TAGStone Capital Inc. raised its position in shares of Amgen by 0.7% in the 4th quarter. TAGStone Capital Inc. now owns 4,129 shares of the medical research company’s stock worth $1,351,000 after acquiring an additional 28 shares in the last quarter. REAP Financial Group LLC raised its position in shares of Amgen by 21.2% in the 4th quarter. REAP Financial Group LLC now owns 252 shares of the medical research company’s stock worth $82,000 after acquiring an additional 44 shares in the last quarter. Finally, GKV Capital Management Co. Inc. raised its position in shares of Amgen by 11.4% in the 4th quarter. GKV Capital Management Co. Inc. now owns 11,969 shares of the medical research company’s stock worth $3,918,000 after acquiring an additional 1,224 shares in the last quarter. Institutional investors own 76.50% of the company’s stock.

Amgen News Summary

Here are the key news stories impacting Amgen this week:

• Positive Sentiment: Amgen received European Commission approval for Imdelltra, a regulatory win that could expand its cancer-treatment revenue opportunity in Europe. EC approval for Amgen’s Imdylltra
• Positive Sentiment: Amgen said it will present new data across rare autoimmune and inflammatory diseases at EULAR 2026, with updates supporting UPLIZNA and TAVNEOS, which may reinforce confidence in its specialty-drug growth. Amgen to Present New Data Across Rare Autoimmune and Inflammatory Diseases at EULAR 2026
• Positive Sentiment: Amgen announced it will present at the Goldman Sachs 47th Annual Global Healthcare Conference, which could keep investor focus on its strategy and pipeline progress. Amgen to Present at the Goldman Sachs 47th Annual Global Healthcare Conference
• Neutral Sentiment: Amgen’s appearance at the Jefferies Global Healthcare Conference is keeping the stock in the spotlight, but the transcript itself does not add a clear new catalyst. Amgen Inc. (AMGN) Presents at Jefferies Global Healthcare Conference 2026 Transcript
• Neutral Sentiment: Amgen is also getting some broader attention from commentary on AI adoption in biotech and analyst notes on healthcare names, but these items appear more informational than stock-moving. The CEO who loves AI autodidacts — and desperately needs his experts Analysts Offer Insights on Healthcare Companies: Amgen (AMGN) and Thermo Fisher (TMO)

Amgen Stock Up 2.2%

AMGN stock opened at $345.60 on Friday. Amgen Inc. has a twelve month low of $267.83 and a twelve month high of $391.29. The company has a quick ratio of 1.01, a current ratio of 1.26 and a debt-to-equity ratio of 5.65. The firm has a market cap of $186.52 billion, a PE ratio of 24.05, a price-to-earnings-growth ratio of 3.39 and a beta of 0.42. The business has a 50 day moving average of $341.44 and a 200 day moving average of $345.44.

Amgen (NASDAQ:AMGN) last posted its quarterly earnings data on Thursday, April 30th. The medical research company reported $5.15 earnings per share for the quarter, beating analysts’ consensus estimates of $4.77 by $0.38. Amgen had a return on equity of 137.41% and a net margin of 20.96%.The company had revenue of $8.62 billion during the quarter, compared to analyst estimates of $8.58 billion. During the same quarter last year, the company earned $4.90 EPS. The firm’s revenue for the quarter was up 5.8% on a year-over-year basis. Amgen has set its FY 2026 guidance at 21.700-23.100 EPS. On average, research analysts forecast that Amgen Inc. will post 22.38 EPS for the current fiscal year.

Insider Buying and Selling

In other Amgen news, SVP Nancy A. Grygiel sold 1,237 shares of the stock in a transaction on Monday, May 4th. The stock was sold at an average price of $323.73, for a total transaction of $400,454.01. Following the sale, the senior vice president directly owned 7,009 shares in the company, valued at approximately $2,269,023.57. This trade represents a 15.00% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Corporate insiders own 0.85% of the company’s stock.

Analysts Set New Price Targets

Several brokerages have recently issued reports on AMGN. Truist Financial increased their target price on Amgen from $325.00 to $327.00 and gave the stock a “hold” rating in a research report on Friday, May 1st. Canaccord Genuity Group began coverage on Amgen in a research report on Monday, April 20th. They set a “hold” rating and a $366.00 price objective for the company. UBS Group raised their price objective on Amgen from $390.00 to $400.00 and gave the company a “buy” rating in a research report on Monday, April 13th. The Goldman Sachs Group raised their price objective on Amgen from $415.00 to $425.00 and gave the company a “buy” rating in a research report on Friday, May 1st. Finally, Guggenheim reduced their price objective on Amgen from $351.00 to $340.00 and set a “neutral” rating for the company in a research report on Monday, May 4th. Two research analysts have rated the stock with a Strong Buy rating, thirteen have issued a Buy rating, fourteen have issued a Hold rating and two have issued a Sell rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of “Hold” and an average target price of $355.19.

About Amgen

Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen’s commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.